Spinogenix Announces WHO Approval of `tazbentetol`
01 Dec 2025 //
PR NEWSWIRE
Spinogenix Unveils Phase 2A Results For SPG302, In ALS
04 Nov 2025 //
PR NEWSWIRE
Spinogenix Reveals Spg302`s Neuroprotective Effects In Glaucoma
16 Oct 2025 //
PR NEWSWIRE
Spinogenix Gets FDA IND Clearance For ALS Therapy SPG302
29 May 2024 //
GLOBENEWSWIRE

Market Place
Sourcing Support